Why IMU is a multi multi bagger, page-25688

@Taureanbull

This is meant to read "Of the 40 evaluable patients in the trial dubbed MAST, nearly half have remained on treatment for more than 3 months and 3 patients have remained on treatment for more than 200 days"
30 months is longer than the trial has been running + they would have said more than half have been on treatment more than 200 days, (however it is only 3).

@Champee Look to what the company is saying re updates...(below). The only updates we are getting between now and early next year are on Azer-Cel. ... as you can see, the only Vaxinia expected is maybe another indication expansion. Otherwise it is all Acer-cell Ph 1b prelim update + Azer cell 2025. I expect the best to hope for is a licence deal to drop (re Azer-cell) in the next 6-9 months, post 1b results. But Vaxinia it appears all is pretty quiet.
\